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Background: Adiponectin, an adipocyte-specific plasma protein, has been shown to   accumulate 
in injured endothelial cells during development of atherosclerotic lesions. In this study, we 
investigated the potential of different adiponectin subfractions with special emphasis on globular 
adiponectin (gAd) to recognize and visualize atherosclerotic lesions.
Methods: Recombinant mouse gAd and subfractions of full-length adiponectin (ie, trimeric, 
hexameric, and oligomeric forms) were fluorescence-labeled. Aortas of wild-type and apoprotein 
E-deficient mice fed a high cholesterol diet were dissected and incubated with the labeled 
  biomarkers. Imaging was performed using confocal laser scanning microscopy.
Results: Confocal laser scanning microscopic images showed that gAd binds more strongly 
to atherosclerotic plaques than full-length adiponectin subfractions. Further, we showed that 
gAd accumulates preferentially in endothelial cells and the fibrous cap area of plaques. Here 
we demonstrate for the first time that gAd recognizes atherosclerotic plaques on aortic sections 
of apoprotein E-deficient mice.
Conclusion: These results suggest that gAd, in addition to its physiological properties, is also 
suitable as a target molecule for prospective diagnostic strategies in imaging atherosclerotic 
lesions.
Keywords: adiponectin subfractions, atherosclerosis, fibrous cap, globular adiponectin,   vascular 
imaging
Introduction
Accumulating evidence suggests that adipose tissue is a highly active endocrine organ1 
producing potent anti-inflammatory proteins in its normal state.2 Probably the most 
important is adiponectin,3 which is predominantly synthesized by adipocytes.4 The basic 
structure of the full-length form of adiponectin (fAd) is a 247 amino acid protein with 
four domains, ie, an amino terminal signal sequence, a nonconserved variable region, 
a collagenous domain, and a carboxyterminal globular domain.5 In the bloodstream, 
adiponectin circulates at concentrations of 2–30 µg/mL of blood6 and in different 
molecular weight forms, named high molecular weight (oligomer), medium molecular 
weight (hexamer), and low molecular weight (trimer) adiponectin.7,8 Interesting to note 
is that these subfractions exert markedly different biological functions.9
Adiponectin is thought to protect against diabetes and atherosclerosis.10 Li et al 
showed that local treatment with adiponectin reduces atherosclerotic plaque size in 
rabbits by decreasing the expression of vascular cell adhesion molecule-1 (VCAM-1) 
and intercellular adhesion molecule-1 (ICAM-1) in the vascular walls.11 Furthermore, 
hypoadiponectinemia was found to be a significant predictor of endothelial dysfunction Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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in both peripheral and coronary arteries.12,13 In subjects with 
metabolic syndrome, a significant negative correlation was 
observed between serum adiponectin concentrations, plaque 
volume, and highly sensitive C-reactive protein levels.14 
Moreover, Waki et al showed that leukocyte elastase secreted 
from activated monocytes and/or neutrophils can cleave 
fAd.15 This cleavage might be the reason for the generation 
of the 17 kDa globular fragment of adiponectin (gAd), which 
is found at lower levels (about 1% of total adiponectin) in the 
circulation.16 gAd was shown to increase insulin-stimulated 
glucose uptake and to boost β-oxidation of fatty acids,17,18 
while other functions remain controversial.19,20
Two main receptors are known to bind adiponectin, 
namely adipoR1 and adipoR2.21 AdipoR1 is expressed 
mainly on vascular smooth muscle cells and endothelial cells, 
predominantly binding gAd. AdipoR2 binds both gAd and 
fAd and is highly expressed on hepatocytes, and in smaller 
amounts in the hypothalamus and on brain endothelial cells.22 
Furthermore, fAd was shown to bind to T-cadherin23 and to 
the multifunctional protein, calreticulin.24
With respect to the atherosclerotic scenario, adiponectin 
was found to accumulate in the subendothelial space of vascular 
walls when the endothelial barrier is injured. There it binds to 
different types of collagen present in the vascular intima.25 In 
contrast, adiponectin was not detected in the subendothelial 
space of human atherosclerotic lesions with an intact 
endothelium.26 Based on these observations, we hypothesized 
that distinct isoforms of adiponectin might show different 
binding affinities to atherosclerotic lesions in the vascular wall. 
We analyzed the potential of fluorescence-labeled gAd and 
fAd subfractions (fAd-Sfs) to bind to atherosclerotic lesions in 
apoprotein E-deficient mice. Consecutive cell culture studies 
were performed to identify target structures which might be 
responsible for specific bindings.
Materials and methods
reagents
Recombinant mouse gAd raised in Escherichia coli and a 
monoclonal mouse antihuman adiponectin antibody (used 
as the primary antibody) were purchased from Atgen, 
Korea, and fAd-Sfs raised in human embryonic kidney cells 
were from Biovendor, Czech Republic. A rabbit antihuman 
collagen type I antibody (Rockland Immunochemicals, 
Philadelphia, PA) was used as a positive control, and 
  nonspecific rat antihuman IgG2a as a negative control, 
similar in molecular weight (150 kDa) to the fAd-Sf hexamer 
(167 kDa). AlexaFluor488-prelabeled rat antimouse CD31 
and rat antimouse CD68 antibodies were used as endothelial 
cell and macrophage markers, respectively (AbD Serotec, 
Dusseldorf, Germany). For further comparative staining 
experiments, mouse interleukin 10, raised in E. coli, from 
Genescript (Piscataway, NJ) was used because it has a 
similar molecular weight (19 kDa) to gAd (17 kDa). In each 
case, two anti-AdipoR1 and anti-AdipoR2 antibodies were 
  purchased (rabbit antimouse antibodies, LifeSpan Biosci-
ences, Seattle, WA; goat antimouse antibodies, Santa Cruz, 
CA), as well as a sheep antimouse calreticulin antibody 
(Abcam, Cambridge, UK). As a long wavelength emitting 
dye, Atto655 (ATTO-TEC GmbH, Siegen,   Germany), was 
used either as a maleimide-functionalized label (Atto655-
Mal) or as an amine reactive carboxylic acid succinimidyl 
ester (Atto655-NHS). As a second dye, Alexa Fluor® 
488   carboxylic acid succinimidyl ester (Alexa488-NHS, 
  Invitrogen, Carlsbad, CA), was chosen to gain a reproducible 
differentiation in double-labeling experiments after incuba-
tion of the tissue with Atto655.
Fluorescence labeling
Labeling procedures followed the standard protocols 
  recommended by the supplier of reactive fluorophores (http://
www.atto-tec.com). Slight alterations in molar ratios of dye 
and protein/antibody were performed to preserve the maxi-
mum binding efficiency to the target protein. In the case of 
gAd, labeling was performed with Atto655-Mal coupling 
to the single cysteine residue within the protein using a 
20-fold molar excess of the dye under basic conditions in 
phosphate-buffered saline (10 mM, 150 mM NaCl, pH 8.0). 
Full-length subfractions of adiponectin, rat antihuman IgG2a, 
and   rabbit and goat antimouse AdipoR2 antibodies were 
labeled with amine-reactive Atto655-NHS, labeling the side 
chains of lysine residues. For the labeling of the fAd-Sfs and 
interleukin 10, a 2-molar excess of Atto655-NHS referred to 
the hexamer (fAd-Sfs) and monomer (interleukin 10) content 
was used. Rat antihuman IgG2a and antimouse AdipoR2 
antibodies were labeled under equimolar conditions with 
Atto655-NHS. Rabbit antihuman collagen type I, rabbit and 
goat antimouse AdipoR1, and sheep anticalreticulin antibod-
ies were labeled with Alexa488-NHS also using equimolar 
dye/protein ratios. All NHS-based labeling procedures 
were performed in 150 mM bicarbonate buffer containing 
5 mM ethylenediamine tetra-acetic acid at pH 8.3. Labeling 
was carried out at room temperature followed by extensive 
dialysis at 4°C to stop the reaction and remove nonbound 
dye. Dialysis was performed in microdialysis tubes with a 
molecular weight cutoff from 5–50 kDa depending on the 
molecular mass of the labeled protein.Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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sDs-PAge and Western blot analysis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) techniques were used for the detection of all 
fluorescence-labeled adiponectin isoforms, antibodies, and 
unspecific IgG. All additional reagents were purchased from 
Bio-Rad Laboratories, München, Germany. Labeled and native 
proteins were diluted with double-distilled water and mixed 
in a ratio of 1:1 with Laemmli sample buffer. Neither heat 
denaturation nor β-mercaptoethanol was applied. gAd was 
then applied on an 18% gel. fAd-Sfs, unspecific IgG, and all 
antibodies were applied on 10% Tris-HCl precast gels. A broad 
range prestained SDS-PAGE standard was used for the size 
mapping of all protein fractions. After fluorescence imaging of 
the labeled proteins excited at λflu = 750 nm (Maestro In Vivo 
Imaging System™, CRi, Woburn, MA), the gels were control 
stained with Bio-SafeTM Coomassie G250 stain.
Western blotting was used for examination of possible 
steric changes in gAd and fAd-Sfs due to the fluorescence-
labeling process. Samples from unstained precast gels 
were blotted to polyvinylidene difluoride membranes. 
Immunoblots were incubated with the primary monoclonal 
mouse antihuman adiponectin antibody, detected using a 
horseradish peroxidase-conjugated goat antimouse secondary 
antibody, and visualized by the chemoluminescence reaction 
with the SuperSignal® West Femto maximum sensitivity 
substrate (all from Pierce Protein Research Products, 
Rockford, IL).
During the labeling reaction for gAd, small amounts of 
gAd dimers and trimers were formed which could be detected 
by Coomassie staining and Western blotting, respectively 
(Figure 1A). All fAd-Sfs were labeled quantitatively, whereby 
a shift from the dominant hexameric form in the unlabeled 
state to the monomeric, trimeric, and oligomeric fractions dur-
ing the reaction was detected by Coomassie staining. Western 
blotting confirmed the detection of all fAd-Sfs and, most 
strongly, the hexameric and oligomeric forms (Figure 1B).
Animal experiments
All animal experiments were approved by the Ministry 
of Science and Research, Austria. Apoprotein E-deficient 
mice with a C57Bl/6J genetic background (Charles River 
Laboratories, Brussels, Belgium) were fed starting at the 
age of 4 months with a western-type (21% XL) experimental 
food (Ssniff Spezialdiaeten GmbH, Soest, Germany) 
for 2–3 months. Age-matched wild-type mice (Medical 
University of Vienna, Austria) were used as a control strain. 
Due to the fact that no gender-specific differences during 
the staining trials were observed, the experiments were 
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Figure 1 Atto655 labeling of adiponectin isoforms. Free dye was eliminated by dialysis. sodium dodecyl sulfate polyacrylamide gel electrophoresis (sDs-PAge) visualization 
was performed by fluorescence imaging and shows the signals of the fluorescence-labeled proteins. Protein size was determined by comparison with a broad range of 
prestained SDS-PAGE standards (Bio-Rad Laboratories, München, Germany). Identification of the proteins was verified using a monoclonal mouse antihuman adiponectin 
antibody, indicating that no steric changes occurred during the labeling reaction. (A) The sole cysteine residue of globular adiponectin was labeled with the dye via a maleimide 
group. 5 µg of the unlabeled and 10 µg of the labeled globular adiponectin was applied for polyacrylamide gel electrophoresis, half thereof for Western blotting analysis. 
(B) Lysines of the full-length adiponectin subfractions were labeled with the dye in a molar ratio of 1:2 (corresponding to the full-length adiponectin subfraction hexameric 
form) via nhs ester bonds. 2 µg of the unlabeled and 2 µg and 10 µg of the labeled full-length adiponectin subfractions were applied for polyacrylamide gel electrophoresis, 
a quarter thereof for Western blotting analysis.
Abbreviations: FL, fluorescence label; WB, Western blot.Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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performed independent of gender. Injured endothelium 
was defined as the activated endothelial layer covering 
the atherosclerotic lesions of apoprotein E-deficient mice. 
For each ex vivo staining trial, three mice were randomly 
sacrificed with an overdose of isoflurane (Abbott Ges 
mbH, Wien, Austria), the chest opened, and the circulation 
immediately rinsed with phosphate-buffered saline (pH 7.4) 
for 15 minutes by perfusing the heart with an injection needle 
and transecting the vena cava. The aorta, including the aortic 
arch, were dissected, cut open, washed with phosphate-
buffered saline (pH 7.4) and transferred to Krebs-Henseleit 
solution (118 mM NaCl; 25 mM NaHCO3; 2.8 mM CaCl2 2 
H2O; 1,17 mM MgSO4 7 H2O; 4,7 mM KCl; 1.2 mM KH2PO4; 
2 mg/mL glucose; pH 7.4) to maintain physiological activity 
of the tissue, and coevally blocked with 1% bovine serum 
albumin (Sigma-Aldrich, St Louis, MO) for 1 hour at room 
temperature. For control experiments, aortic sections were 
preincubated to excess with native gAd (60 µg/mL) for 1 hour 
at 4°C to saturate possible adiponectin-binding regions. The 
samples were then incubated with the fluorescence-labeled 
proteins or antibodies (3 or 20 µg/mL of fluorescence-labeled 
gAd; 20 µg/mL of unspecific rat antihuman IgG2a, rabbit 
antihuman collagen type I, or sheep antimouse calreticulin 
antibody; 30 µg/mL of fAd-Sfs; 10 µg/mL of interleukin 
10; 50 µg/mL of rabbit or goat antimouse adipoR1 or anti-
adipoR2 antibody) for 1–2 hours at 37°C, with shaking in 
the dark to avoid fluorochrome bleaching. Hoechst 33342 
fluorescence dye (1 µg/mL, Invitrogen) was added to stain the 
cell nuclei. The aortic sections were then washed 3–4 times 
in phosphate-buffered saline (pH 7.4), put on a glass slide, 
covered with polyvinyl alcohol mounting medium with 1,4-
diazabicyclo[2.2.2]octane (Sigma-Aldrich), adjusted under a 
stereomicroscope, and squeezed with a cover slip.
in vitro studies
Human endothelial colony-forming cells were cultured in 
endothelial growth medium (EGM-2, Lonza, Walkersville, 
MD) supplemented with 10% fetal bovine serum.27 Selected 
cultures were treated with 30 µg/mL acetylated low density 
lipoprotein to apply lipid stress by changing the medium once 
a day. Control cultures were treated in the same manner, but 
were not exposed to acetylated low density lipoprotein. On 
day 7, the cells were stained with 10 µg/mL Atto655-labeled 
gAd for 1 hour at 37°C and washed with medium.
The endothelial colony-forming cells used comply with 
American Heart Association guideline requirements. The 
cells are defined by the cell surface markers CD31+/CD34+/
CD45-/CD115-, lack hematopoietic potential, contribute 
to de novo blood vessel formation in vivo, and demonstrate 
clonal proliferative potential.28 Differentiation into endothe-
lial cells was demonstrated by upregulation of genes/proteins 
not previously expressed by the experimental cell population, 
but normally expressed by primary endothelial cells and not 
expressed by other cell lineages.29
Fluorescence imaging
All fluorescence and transmitted light images of the aortic 
samples (Z-Stack images) and cultured cells were acquired 
using the LSM 510 META Axiovert 200M Zeiss confocal 
system (Jena, Germany), operating with a 25 mW laser diode 
tuned to 405 nm for Hoechst staining of the cell nuclei, a 
30 mW argon laser tuned to 488 nm for visualization of the 
AlexaFluor488-labeled antibodies, and a 5 mW HeNe laser 
tuned to 633 nm for visualization of all Atto655 labeled 
proteins. Images were collected using a 40× Plan-Neofluar 1.3 
DIC oil immersion objective and a multitrack configuration, 
whereby the Hoechst, AlexaFluor488, and Atto655 signals 
were sequentially collected with BP 420–480 nm, BP 
505–550 nm, and BP 679–743 nm filters after excitation 
with 405 nm, 488 nm, and 633 nm laser lines, respectively. 
In the sequential acquisitions for all three channels, the Zeiss 
AIM software version 4.2 was used. All confocal images were 
acquired with a frame size of 1024 × 1024 pixels averaged 
three times.
Results
globular adiponectin accumulates 
selectively in the outer layers of  
atherosclerotic plaques
The binding affinity of gAd was evaluated for imaging 
of atherosclerotic lesions. Preparations from the inner 
aortic surface of apoprotein E-deficient and C57Bl6/J 
wild-type mice were imaged by confocal laser scanning 
microscopy, either unstained or stained with 20 µg/mL 
Atto655 fluorescence-labeled recombinant mouse gAd 
(gAd-Atto655). Sections from apoprotein E-deficient mice 
showed abundant atherosclerotic plaques of different sizes 
(Figure 2A, left panel), while aortic sections from the 
control mice showed neither atherosclerotic lesions nor a 
fluorescence signal of gAd-Atto655 (insert, right panel in 
Figure 2A). In contrast, a strong signal was detected on all 
atherosclerotic plaques from apoprotein E-deficient mice 
(Figure 2A, middle panel), while the surrounding surface 
area showed no fluorescence signal (Figure 2A, right panel). 
Moving from the top of a plaque down to the surrounding Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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surface, the Z-Stack images revealed that gAd-Atto655, in 
contrast with the Hoechst nucleus dye, did not penetrate 
into the lipid core but stained the outer layer of the plaques 
(Figure 2B).
To support our results, costaining experiments were 
performed. Double-staining of the lesions confirmed that 
gAd is localized inside the endothelial cells of atherosclerotic 
plaques. Endothelial cells were identified using an 
AlexaFluor488-labeled antibody against the endothelial 
cell marker CD31 (Figure 3A). In another double-staining 
experiment using an AlexaFluor488-labeled antibody against 
collagen type I, colocalization of gAd with collagen type I 
was observed (Figure 3B).
To exclude nonspecific binding of the fluorescent dye to 
the plaque, some aortic sections were preincubated with a 
large amount of unlabeled gAd. The sections were then stained 
with gAd-Atto655 as usual. On confocal laser scanning 
microscopy, we saw that the gAd-Atto655 signal from the 
atherosclerotic plaques of the presaturated aortic sections was 
significantly reduced compared with the nonsaturated sections 
(Figure 3C). We used Atto655-labeled mouse interleukin 10 
for further comparative staining experiments because of its 
molecular weight being similar to gAd (gAd 17 kDa versus 
interleukin 10 19 kDa), and observed a different staining 
pattern with confocal laser scanning microscopy. As seen 
in Figure 3D, interleukin 10 penetrated the atherosclerotic 
plaques and did not preferentially accumulate in the outer 
layer, as did gAd.
Binding efficiency of fAd-Sfs lower than  
of gAd for atherosclerotic plaques
The atherosclerotic plaque binding efficiency of gAd was 
then compared with that of the fAd subfractions. Aortic 
  sections from apoprotein E-deficient and wild-type mice were 
stained with either 30 µg/mL Atto655 fluorescence-labeled 
recombinant mouse fAd-Sfs (fAd-Sfs-Atto655) or 3 µg 
A
B
Plaque control
TLI
1 µm 10 µm 20 µm
WT
Plaque + gAd Aortic endothelium + gAd
Figure 2 Globular adiponectin accumulates in the outer layer of atherosclerotic plaques. Aortic sections of apoprotein E-deficient and wild-type mice were incubated with 
globular adiponectin-Atto655 20 µg/mL, except for control sections. sections were squeezed between a glass slide and a cover slip and visualized by confocal laser scanning 
microscopy (fluorescence and transmitted light). (A) Optical sections from aortic preparations projected into one plane. For each image, a series of 20–30 fluorescence 
images in Z (1–2 µm consecutive intervals) were projected in a single image. The nuclei (n) were stained with hoechst (blue). control plaque (left panel) and accumulation 
of globular adiponectin (red) on atherosclerotic plaques (middle panel) are shown; globular adiponectin does not bind to the intact aortic endothelium of apoprotein-E or 
wild-type mice (right panel). (B) Overlay of single Z-plane fluorescence and transmitted light images from a globular adiponectin-Atto655-stained plaque at different relative 
depth, as indicated on the left side bar in each panel are shown. 
Note: scale bars indicate 50 µm.
Abbreviations: WT, wild type; TLI, transmitted light image.Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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gAd-Atto655. We found that the aortic surface   surrounding 
the atherosclerotic plaques showed no signal after staining 
with fAd-Sfs-Atto655, while the plaques themselves showed 
a weak signal (Figure 4, middle panel). However, the staining 
signal was very faint compared with the signal obtained from 
gAd-Atto655. Even at equimolar concentrations, evaluated in 
relation to the 167 kDa fAd hexamer, gAd showed the better 
staining signal (Figure 4, right panel). The rat IgG negative 
control showed no staining at all (Figure 4, left panels). 
To identify the atherosclerotic plaque regions, the same aortic 
sections were costained with 5 µg/mL of a ready-labeled 
antibody against the macrophage marker CD68, shown in 
the other small inserts in Figure 4.
High binding efficiency of gAd to 
athero  sclerotic plaque surface
The expression of known adiponectin receptors in the athero-
sclerotic plaque scenario was examined to look for specific 
A gAd + cell nuclei
Aortic endothelium
CD31 Merge
Merge Collagen type l gAd
gAd pre-saturated control gAd + cell nuclei IL-10 + cell nuclei D
B
C
0
10µm
Figure 3 Globular adiponectin is localized in the fibrous cap of atherosclerotic plaques. (A) For double-staining experiments, aortic sections of apoprotein E-deficient mice 
were coincubated with globular adiponectin-Atto655 20 µg/mL and AlexaFluor488-labeled rat antimouse cD31 antibody. The nuclei were stained with hoechst (blue). 
Single Z-plane fluorescence images were taken at a depth of 4 µm from the top of an atherosclerotic plaque showing the localization of globular adiponectin-Atto655 in the 
endothelial layer. The aortic surface is shown in the small inserts. (B) Aortic sections of apoprotein E-deficient mice were coincubated with globular adiponectin-Atto655 and 
AlexaFluor488-labeled rabbit antihuman collagen type I antibody. Single Z-plane fluorescence images were taken at a depth of 7 µm from the top of an atherosclerotic plaque, 
showing colocalization of globular adiponectin and collagen type i. (C) For negative control experiments, aortic sections were preincubated with a high amount of native 
globular adiponectin. A stack of optical sections from an atherosclerotic plaque projected into one plane showed only a weak globular adiponectin-Atto655 signal, compared 
with the plaque image in the left panel in B. (D) Single Z-plane fluorescence light images from a globular adiponectin-Atto655 and an interleukin 10-Atto655-stained plaque 
at a depth of 10 µm from top of the plaque. images show the different staining patterns between globular adiponectin and interleukin 10.
Notes: scale bars: A and C, 50 µm; B, 20 µm. Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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interactions of gAd with the atherosclerotic plaque surface. 
Aortic sections of apoprotein E-deficient mice were stained 
with fluorescence-labeled antibodies against AdipoR1 and 
AdipoR2, and against calreticulin.
While the gAd staining signal was detected at the surface 
of atherosclerotic plaques (Figure 5A and B, left panels), 
the antibodies against the gAd binding proteins, adipoR2 
and calreticulin, showed staining signals from under the 
surface of the plaques (Figure 5A and B, middle and right 
panel). Thus, no colocalizations between gAd and these 
adiponectin-binding domains could be shown. Neither of the 
two antiadipoR1 antibodies generated a staining signal, either 
on the plaque surface or below (data not shown).
globular adiponectin accumulation  
in lipid-stressed endothelial  
colony-forming cells
To understand the results from the staining of aortic mouse 
sections better, fluorescence-labeled gAd was evaluated in in 
vitro studies. Human endothelial colony-forming cells were 
cultured under proangiogenic and lipid stress conditions. The 
cells were incubated with 10 µg/mL of the same recombinant 
Anti-rat lgG control
CD68 CD68 aortic endothelium aortic endothelium
fAd-Sfs gAd
Figure 4 Binding efficiency of the full-length adiponectin subfractions to atherosclerotic plaques is much lower than that of globular adiponectin. Aortic sections of apoprotein 
E-deficient mice were incubated with unspecific rat antihuman IgG2a labeled with Atto655 as negative control (left) or full-length adiponectin subfraction-Atto655 30 µg/mL 
(middle) or globular adiponectin-Atto655 3 µg/mL (right). The inserts shown in the left and middle panels on the left side are positive controls, staining atherosclerotic plaques 
with an AlexaFluor488-prelabeled antibody against the macrophage marker cD68.
Note: scale bars: 50 µm.
A
B
gAd AdipoR2 Calreticulin
Figure 5 High binding efficiency of globular adiponectin to atherosclerotic plaques is independent of interactions with known adiponectin receptors. Aortic sections of 
apoprotein E-deficient mice were incubated with gAd-Atto655 20 µg/mL (left panel) or fluorescence-labeled rabbit antimouse adipoR1 and adipoR2 antibody (middle), or 
sheep antimouse calreticulin antibody (right). (A) Single horizontal Z-plane fluorescence images from atherosclerotic plaques. (B) Overlay of vertical fluorescence and 
transmitted light images. Yellow arrows indicate plaque surface globular adiponectin staining; white arrows indicate plaque interior adipoR2 staining; orange arrows indicate 
plaque interior calreticulin staining. Anti-adipor1 showed no staining signal (data not shown). 
Note: scale bars: A, 20 µm; B, 10 µm.Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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mouse gAd-Atto655 as used for the aortic sections. An 
amino acid sequence alignment of mouse gAd with human 
gAd showed 91% identity and no gaps between amino acid 
sequences. Endothelial colony-forming cells, either cultured 
under endothelial cell culture conditions or treated with acety-
lated low density lipoprotein, did not bind gAd (Figure 6). 
Only a subset of acetylated low density lipoprotein-treated 
endothelial colony-forming cells showed an accumulation of 
gAd, which is marked by the yellow arrows in Figure 6. No 
signal was detected in cells treated with unspecific rat IgG 
(insert shown in Figure 6).
Discussion
Identification of atherosclerotic disease in its early stages and 
the need to follow the progression of atherosclerosis is still 
a challenge for medical imaging, which is limited not only 
by the properties of present imaging techniques, but also 
by the availability of specific biomarkers.30 In the present 
study, adiponectin was evaluated as a promising new target 
sequence. We showed for the first time that gAd, compared 
with fAd-Sfs, has higher binding efficiency for atherosclerotic 
plaques in apoprotein E-deficient mice, but not for the area 
surrounding the atherosclerotic plaques. Localization of gAd 
in endothelial cells and colocalization with collagen type I 
were observed, but no colocalizations of gAd with known 
adiponectin receptors or adiponectin binding proteins were 
found, pointing to a thus far unknown binding reaction.
Further aortic staining experiments showed that gAd 
generated staining patterns at atherosclerotic plaques 
markedly different from those of interleukin 10, although 
both gAd and interleukin 10 have approximately the same 
molecular weight and were labeled with the same fluorescence 
dye. Thus, the observed staining patterns at atherosclerotic 
plaque structures were generated by the proteins and not by 
an unspecific binding reaction of the fluorescence dye. Cell 
culture experiments, which should characterize its binding 
affinity in more detail, showed that gAd was internalized by 
endothelial colony-forming cells, but only the subset which 
was obviously injured by acetylated low density lipoprotein 
treatment. Based on our observations, compared with the 
Fluorescence light Merge
Blank
Blank
Unspec. lgG
+ acLDL
Control
Transmitted light
Figure 6 globular adiponectin accumulates in lipid-stress injured human endothelial colony forming cells. endothelial colony forming cells were cultured in the presence or absence 
(control) of acetylated low density lipoprotein and incubated with 10 µg/mL globular adiponectin-Atto655 or nonspecific IgG-Atto655 for 1 hour at 37°c. imaging was performed 
by confocal laser scanning microscopy. Unstained (blank) samples are shown as inserts in the middle panels. Yellow arrows indicate globular adiponectin accumulations. 
Note: scale bar: 25 µm.
Abbreviations: acLDL, acetylated low-density lipoprotein; unspec., unspecific.Biologics:   Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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data of Ouchi et al26 who showed that adiponectin was only 
detected at the injured atherosclerotic vascular wall, we 
hypothesize that the globular fragment of the total circulating 
amount of adiponectin can accumulate preferentially in 
atherosclerotic plaques with a thick fibrous cap.
Both anti-inflammatory actions and proinflammatory 
mechanisms have been described with reference to gAd. 
Recently, Kamio et al showed that gAd pretreatment of 
RAW264 cells significantly inhibited lipopolysaccharide-
induced tumor necrosis factor alpha (TNF-α) expression 
and enhanced the expression of interleukin 10.31 Whereas a 
study by Zhang et al showed that gAd suppresses TNF-α-
induced ICAM-1 expression in vascular endothelial cells at 
concentrations higher than 1 µg/mL, the suppressive effect 
is lost at concentrations lower than 0.25 µg/mL.32
In support of the proinflammatory actions of gAd, Hattori 
et al showed that gAd activates NF-KB in vascular endothelial 
cells, which induces the expression of proinflammatory and 
adhesion molecule genes.33 gAd increased the expression 
of 187 genes, including ICAM-1, VCAM-1, monocyte 
chemoattractant protein-1, and E-selectin,33 and also 
increased the expression of interleukin 634 and granulocyte 
colony-stimulating factor.
Within this controversial scenario, we agree with the 
concept of Sun et al19 that the balance between proinflam-
matory and anti-inflammatory effects might depend on the 
concentration of gAd. While high concentrations of gAd may 
be proinflammatory, moderately high or low concentrations 
could act in an anti-inflammatory manner.
Shapiro and Scherer showed that the structure of gAd 
revealed an unexpected homology with the TNF family.35 
Hence, we speculate that the homology between gAd and 
TNF-α may be a reason for the proinflammatory effects of 
abundant amounts of gAd, because it is known that gAd, like 
TNF-α, strongly activates NF-KB.36 Otherwise, gAd may 
reduce TNF-α expression37 due to a competitive reaction 
based on the similar structure of both proteins, a theory which 
should be elucidated in further experiments.
Little is known about the distribution of adiponectin 
receptors in endothelial and smooth muscle cells, especially 
in atherosclerotic regions.38 Chinetti et al found both adipoR1 
and adipoR2 to be present in atherosclerotic human lesions, 
with a particularly constant amount of adipoR2 in activated 
macrophages.39 This may explain the detection of the 
adipoR2 signal in our studies inside macrophage-loaded 
atherosclerotic plaques, but at the same time this illustrates 
that the binding of gAd in the outer layer of the atherosclerotic 
plaques is independent of adipoR2. Like adipoR2, the 
calreticulin signal was detected in the plaques inside and 
surrounding the cell nuclei. It is known that calreticulin is 
a multifunctional protein that acts as a major Ca2+-binding 
protein in the lumen of the endoplasmic reticulum. It was 
also found in the nucleus, suggesting that it may have a 
role in transcription regulation.40 Regarding the data by 
Takemura et al24 showing very detailed interactions between 
fAd and calreticulin in their in vitro studies, we found that 
the strong gAd signal, which was observed in our ex vivo 
experimental model in the surface area of the plaques cannot 
be generated through a direct interaction with calreticulin, 
which is detected beneath and not on the surface. Further, 
the adiponectin binding receptor, T-cadherin, is known to be 
upregulated in atherosclerotic lesions.38 However, because 
T-cadherin is considered to be a receptor for the medium 
molecular weight and high molecular weight adiponectin 
subfractions and not for gAd,23 this protein is not likely to 
be responsible for the intense gAd signal observed at the 
surface of atherosclerotic plaques.
Thus, the reason why the binding efficiency of gAd to 
atherosclerotic lesions is much higher compared with fAd-Sfs 
is not clear at all. We speculate that it could be a matter of 
molecular size. While the circulating amount of fAd contains 
subfractions larger than 60 kDa (originating from the trimeric 
form), the cleaved globular domain has only 17 kDa and 
can therefore better diffuse through the fenestrated cellular 
membrane of the injured aortic endothelium. However, this 
theory remains to be proven in further in vitro studies.
In conclusion, we have outlined distinct differences in 
the binding efficiency of fAd and gAd to atherosclerotic 
lesions. We propose that the high binding efficiency of gAd 
to atherosclerotic plaques represents an inflammation-based, 
mainly receptor-independent, process of accumulation of 
gAd in the fibrous cap of atherosclerotic plaques. For that 
reason, and due to the fact that blood levels of gAd are 
much lower compared with the levels of fAd-Sfs,16 gAd 
seems to be an appropriate targeting sequence. By using 
an optimized “noninflammatory” gAd concentration, gAd 
could be exploited for the imaging of atherosclerotic plaques 
and possibly in therapeutic strategies against emerging 
atherosclerosis, before fatal clinical symptoms like plaque 
rupture and thrombosis occur.
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